Safety and efficacy of atorvastatin in heart transplant recipients

摘要: Abstract Background: Pravastatin and simvastatin prolong survival reduce transplant-related coronary vasculopathy, although low-density lipoprotein (LDL) lowering with these agents is only modest. The objective of this study was to assess the safety moderate dose atorvastatin its efficacy when prior treatment another statin had failed lower LDL Methods: Data from 185 patients were retrospectively evaluated for adverse events, duration exposure (person-days), mean exposure. Changes in lipid parameters, prednisone cyclosporine doses determined. Results: Safety: 48 received 24,240 person-days at a 21 ± 10 mg. Rhabdomyolysis, myositis, myalgias, hepatotoxicity occurred 0, 2, 0 patients, respectively. All events 10-mg dose, within first 3 months, rapidly reversible discontinuation. Efficacy: Thirty-four evaluable analyses pre-atorvastatin 145 38 mg/dl on following statins: pravastatin ( n = 30, 40 0mg), fluvastatin 3, 33 12 mg), 1, mg). After (21 9 mg/day) 133 67 days, reduced 97 24 (relative reduction 31 20%, p Conclusion: Atorvastatin, used close biochemical clinical monitoring, appears be safe effective aggressively heart transplant recipients other statins has achieve goals.